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in a dietary induced model of cerebral capillary
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Background: Probucol has been shown to prevent cerebral capillary disturbances characterized by blood-to-brain
extravasation of plasma derived proteins and neurovascular inflammation in mice maintained on western-styled
diets for 12 weeks. However the effect of probucol on capillary integrity in aging models with capillary dysfunction
is not known.
Methods: Wild-type C57BL6 mice were randomized to a low-fat (LF); saturated-fat (SFA); or SFA + Probucol diet for
up to12 months of intervention.
Results: Mice fed the LF diet had substantially greater parenchymal abundance of plasma derived IgG and apo B
lipoproteins at 12 months, compared to LF mice at 3 months of intervention. Markers of neurovascular
inflammation were also greater at 12 months in LF fed mice compared to LF mice at 3 months. The SFA diet
exacerbated the aging induced parenchymal abundance of IgG and of apo B lipoproteins and neurovascular
inflammation at 12 months. The SFA effects were associated with increased production of intestinal lipoprotein
amyloid-β (Aβ). The co-provision of probucol with the SFA completely abolished heightened inflammation at
12 months. Probucol attenuated SFA-induced capillary permeability but had only a modest inhibitory effect on
parenchymal retention of apoB lipoproteins. The improvements in markers of inflammation and capillary integrity
because of probucol correlated with enterocytic genesis of chylomicron Aβ.
Conclusion: In this long-term feeding study, probucol profoundly suppressed dietary SFA induced disturbances in
capillary integrity but had a more modest effect on age-associated changes.
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Probucol is an older generation cholesterol-lowering
agent once commonly prescribed to reduce cardiovascu-
lar disease risk before the advent of HMGCoA-reductase
inhibitors (statins). However, some studies suggest that
probucol may also have neurovascular benefits. Probucol
was found to prevent cognitive and hippocampal synap-
tic impairments induced by amyloid-beta (Aβ) peptides* Correspondence: J.Mamo@curtin.edu.au
School of Public Health, and CHIRI Biosciences Research Precinct, Faculty of
Health Sciences, Curtin University, Bentley, GPO Box U1987, Perth 6845, WA,
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unless otherwise stated.in mice [1] and in a pilot clinical study in subjects with
early-mid Alzheimer’s disease (AD), probucol was re-
ported to stabilize cognitive decline compared to the
placebo treated group [2]. The mechanisms for the pur-
ported positive effects of probucol in AD and in models
of AD are unknown but are suggested to include de-
creased formation of toxic Aβ oligomers as a conse-
quence of increased Aβ chaperoning [3], or direct
positive effects of the agent on neurovascular integrity
and function [4].
In wild type mice, the short-term (3 months) ingestion
of a diet either supplemented with cholesterol (1% w/w)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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w/w) induced a substantial disruption of blood–brain
barrier (BBB) integrity, resulted in accumulation of
plasma-derived proteins within brain parenchyme [4-6].
The SFA diet had a more profound detrimental effect on
capillary permeability compared to the cholesterol-
supplemented diet, which occurred concomitant with in-
creased cerebral abundance of Aβ that was associated
with apoB lipoproteins. Given that probucol was found
to markedly suppress enterocytic production of lipopro-
tein associated Aβ following 3 months of SFA-feeding
[7], decreased vascular post-prandial exposure to Aβ as-
sociated with apoB lipoproteins may have been one
mechanism by which probucol maintained cerebral ca-
pillary function.
Recent studies suggest that in wild-type mice main-
tained on a low-fat (LF, cholesterol and SFA-free) diet,
capillary permeability will progressively increase 4–5 fold
over a 12-month period compared to mice at 3 months
of age [8]. However, interactive effects of aging with
dietary-fats were reported and include accelerated BBB
permeability as a consequence of the ingestion of SFA.
The study also demonstrated that exaggerated blood-to-
brain kinetics of plasma proteins as a consequence of
aging and fat-feeding results in heightened neurovascu-
lar inflammation. Given these findings and in the con-
text of further considering the potential therapeutic
value of probucol in attenuating neurovascular inflam-
matory disorders associated with ageing and western-
styled diets, longer-term studies are needed. This study
considered the efficacy of probucol in C57BL/6 mice
maintained on LF fed or SFA-fed diet for 12 months.
Results
The body weights, plasma lipids and non-esterified fatty
acids for the treatment groups are provided in Table 1.
Body weights were comparable at 12 months of interven-
tion irrespective of dietary regimen, although weight gain
was transiently greater in mice fed the SFA enriched diets
between 3–12 months of feeding. The SFA diet was well
tolerated and mice were normo-lipidemic throughout theTable 1 Weights, plasma lipids, and non-esterified fatty acids
3 months
LF SFA SFA +
Weight (g) 22.2 ± 0.33 22.7 ± 0.33 22.7
Weight gain (g) - -
Cholesterol (mmol/L) 3.18 ± 0.26 3.13 ± 0.22 0.58 ±
Triglyceride (mmol/L) 0.35 ± 0.023 0.32 ± 0.038 0.44
NEFA (mEq/L) 0.49 ± 0.064 0.70 ± 0.041** 0.34
LF = Low fat, SFA = Saturated fatty acid, NEFA = Non-esterified fatty acid.
Data are shown as mean ± SEM. Statistical significance analyzed with one-way ANO
or at p < 0.01 (**).duration of dietary intervention. Plasma non-esterified
fatty acid (NEFA) were increased in SFA fed mice at
3 months, but were comparable to LF fed controls at
12 months of feeding (Table 1). Whilst the SFA fed diet
had no significant impact on plasma cholesterol, co-
provision of probucol nonetheless lowered plasma chol-
esterol by approximately 80%.
In this study, brain parenchymal abundance of IgG
was used as a measure of non-specific capillary permeabil-
ity. ApoB lipoproteins are exceedingly large macromole-
cules that become enriched with Aβ as a consequence of
SFA feeding. Figure 1A compares the parenchymal abun-
dance of IgG and apoB lipoproteins in mice maintained
on an SFA enriched diet 12 months relative to LF fed con-
trol mice at 3 months. The synergistic effects of probucol
with SFA feeding on parenchymal IgG and apoB are also
illustrated in Figure 1A. Representative images from each
treatment group are provided as Figure 1B. We firstly con-
firm that at 12 months of intervention, IgG and apoB ex-
travasation in LF fed mice was significantly greater
compared to 3 months, indicative of an age-specific ef-
fect. The synergistic effects of SFA with age remained
evident for IgG and apoB within the CTX (Figure 1).
We now show that at 12 months of SFA feeding, probucol
continued to suppress parenchymal accumulation of IgG,
however there was only a modest inhibitory effect on re-
tention of apoB lipoproteins within brain parenchyme.
The effects of probucol on established markers of neu-
rovascular inflammation (glial fibrillary acidic protein
(GFAP) and cyclooxygenase-2 (COX-2)) in mice fed the
LF or SFA-enriched diet are shown in Figures 2A and 3.
Consistent with our previous finding, GFAP within the
cortex were increased in LF fed mice at 12 months of age
compared to 3 months of age. We now also report a sig-
nificant increase of COX-2 in the CTX by aging. The SFA
enriched diet markedly increased GFAP and COX-2 ex-
pression within both brain regions of interest at 12
months of feeding. Probucol completely abolished the
SFA induction of GFAP and COX-2. Potential associations
between inflammation (GFAP and COX-2) and measures
of capillary permeability and brain parenchymal apoB12 months
Probucol LF SFA SFA + Probucol
± 0.33 30.8 ± 1.5 36.4 ± 1.0 32.8 ± 2.5
- 14.3 ± 1.50 21.3 ± 1.02* 13.26 ± 2.53
0.074** 3.25 ± 0.29 2.72 ± 0.12 0.58 ± 0.068**
± 0.034 0.51 ± 0.082 0.45 ± 0.11 0.56 ± 0.13
± 0.041 0.47 ± 0.026 0.40 ± 0.021 0.44 ± 0.051
VA followed by Tukey’s post hoc test (2 tailed, n = 8) is indicated at p < 0.05 (*)
Figure 1 Semi-quantitative 3-D immunomicroscopy for the assessment of blood–brain barrier integrity. The integrity of blood–brain
barrier (BBB) in mice maintained on low-fat (LF) control chow or diet enriched in saturated fatty acids (SFA) with or without probucol for 3 months
(3 M) and 12 months (12 M) was assessed by the cerebral extravasation of plasma proteins, IgG and apolipoprotein (apo) B. (A) 3-D quantitative
immunomicroscopy graphs show the mean voxel intensity of IgG/apoB that are in the parenchyme of cortex (CTX) and hippocampal formation (HPF).
The * shows the statistical significance assessed by one-way ANOVA with Tukey’s post hoc test (p < 0.05, n = 8). (B) Representative images of capillary
vessel integrity are provided. IgG is shown in green, apolipoprotein (apo) B is in red, and nuclei are in blue. The scale bar indicates 100 μm.
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ficients for GFAP versus cerebral IgG and apoB extravasa-
tion were significant. Similarly, COX-2 expression was
also positively associated with parenchymal IgG and apoB.
To explore if the persistent parenchymal abundance of
apoB at 12 months of feeding was associated with the bio-
genesis of enterocytic production of lipoprotein AB and to
explore whether this was one mechanism by which probu-
col regulated parenchymal retention of plasma derivedproteins and inflammatory sequelae, the intestinal produc-
tion of lipoprotein Aβ was determined by measuring the
abundance of enterocytic Aβ and apoB. Mice fed the LF
diet at 12 months of intervention had a remarkable 6-
fold elevation in enterocytic Aβ compared to mice at
3 months of intervention. The substantial increase in
enterocytic Aβ however, occurred without any apparent
change in lipoprotein abundance per se (indicated by
enterocytic apoB) (Figures 4A and 5). Provision of a diet
Figure 2 Semi-quantitative 3-D immunomicroscopy for cerebrovascular and neuronal inflammation. Cerebrovascular and neuronal
inflammation was assessed by 3-D immuno quantitative analysis of the cerebral parenchymal and vascular expressions of GFAP and COX-2 in
cortex (CTX) and hippocampus (HPF) of mice fed with low-fat (LF) or saturated fat (SFA) diet with/without probucol for 3 and 12 months. (A)
Mean voxel intensity of parenchymal GFAP and COX-2 in CTX and HPF is shown. * indicates the statistical significance assessed with one-way
ANOVA followed by Tukey’s post hoc test (p < 0.05, n = 8). (B) Pearson’s correlation coefficient between the GFAP or COX-2 expression and
cerebral IgG/apoB extravasation in each animal was also performed (n = 24).
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enterocytic Aβ. However, in addition the SFA diet also
strongly stimulated chylomicron biosynthesis. The co-
provision of probucol with SFA was found to substan-
tially attenuate the SFA-induced enterocytic abundance
of Aβ by more than 40% (Figures 4A and 3). Probucol
showed more modest suppressive effects on enterocytic
chylomicron apoB abundance. Consistent with the find-
ings in enterocytes, the plasma concentration of Aβ1–40and 1–42 were significantly elevated with 12 months SFA
ingestion, but suppressed by the co-provision of probu-
col (Figure 4B).
Figure 4C considers capillary permeability in the context
of a possible association with postprandial chylomicron
Aβ metabolism. The findings indicate a reasonably strong
positive correlation between enterocytic Aβ and cerebral
capillary permeability. However, the correlation analysis
did not support an association between parenchymal
Figure 3 Immunofluorescent micrographs of cerebral GFAP and COX-2 expression. Representative images of neuroinflammatory GFAP and
COX-2 in mice maintained on low-fat (LF) control chow or diets enriched in saturated fats (SFA) with/without probucol for 3 months (3 M) and
12 months (12 M) are shown. GFAP is shown in pale yellow, COX-2 is in magenta, and nuclei are in blue. The scale bar indicates 100 μm.
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concentration per se (ie. enterocytic apo B) (Figure 4C).
Furthermore, there was a strong correlation of GFAP and
COX2 with enterocytic chylomicron Aβ. There was also
an association of inflammation with chylomicron abun-
dance (apoB), however the correlation coefficient was
markedly weaker (Figure 4D).Discussion
This study investigated in a murine model the efficacy of
probucol to suppress cerebral capillary dysfunction and
heightened neurovascular inflammation that occurs with
aging and long-term ingestion of SFA enriched diets.
Previous studies have equivocally demonstrated the
presence of plasma-derived proteins within brain parench-
yme in mice maintained on SFA enriched diets for 3 to 12
months [4,5,8-10]. Diets enriched in SFA also promote se-
cretion from epithelial cells of the small intestine of Aβ as-
sociated with chylomicrons [7,11,12] and these findings
previously led us to propose that exaggerated exposure to
SFA and/or chylomicron-Aβ compromise capillary perme-
ability. Whatever the mechanism, plasma derived apoB
lipoprotein-Aβ extravasation to brain parenchyme and ex-
aggerated retention upon extracellular matrices has been
demonstrated in mice fed an SFA-enriched diet for 6
months [5]. In more recent studies, synergistic effects of
aging and western styled diets on cerebral capillary dys-
function were demonstrated [8]. Notably however, marked
capillary dysfunction was also shown in aged (12 month)
mice maintained on a LF diet that was free of saturated
fats and cholesterol.
Several lines of evidence suggest that probucol may be
an agent of therapeutic value for individuals with AD [2].
In addition to positive capillary function regulatory effects
in mice maintained for relatively short periods of time on
SFA/cholesterol diets, probucol has other potentially useful
metabolic effects including synaptic potentiation [1]; inhib-
ition of Aβ biogenesis [7]; promotion of Aβ-chaperoning(reduction in formation of toxic oligomers) [3]; vasodila-
tory effects [13]; and anti-oxidant/-inflammatory proper-
ties [4,13]. However, further consideration of probucol in
a therapeutic context for prevention of non-familial AD
would be strengthened by longitudinal in vivo studies in
an aging context.
This study used an established model of BBB dysfunc-
tion induced by aging and exacerbated by the provision of
dietary SFA to explore the effects of probucol on cerebral
capillary function. The dietary intervention was physiolo-
gically relevant with approximately 40% of energy derived
as fats. The SFA diet was well tolerated and mice random-
ized to this treatment were found to be normolipidemic
and had similar body weight to LF fed controls at the con-
clusion of treatment. Probucol predictably lowered plasma
cholesterol but this was not associated with either paren-
chymal extravasation of plasma proteins, or measures of
neurovascular inflammation and so was not considered
further.
In this study, we firstly confirm that parenchymal
extravasation of plasma derived IgG is increased as a con-
sequence of aging and exacerbated by SFA feeding consist-
ent with our previous study [8]. We extend those findings
and now show that parenchymal retention of apoB lipo-
proteins is markedly increased in mice maintained for 12
months on an otherwise healthy LF diet. A synergistic ef-
fect of aging with SFA resulted essentially in a doubling of
the age-induced effect. The co-provision of probucol with
SFA was found to completely abolish the long-term SFA
induced effect, a phenomenon previously reported in mice
maintained on an SFA diet for just 3 months [4]. However,
probucol had no marked effect on the age-associated in-
creased abundance of plasma-derived proteins within
brain parenchyme, only showing parenchymal IgG and
apoB reduction to the 12 months LF level but not to the
3 months LF mice without the ageing effect. Some re-
gional differences in effectiveness were also noted. Probu-
col effectively abolished the SFA induced accumulation of
IgG and apoB within the CTX following 12 months of
Figure 4 Semi-quantitative 3-D immunomicroscopy for small intestinal production and secretion of amyloid-β and apolipoprotein B,
and plasma amyloid-β. The production within the enterocytes and secretion into the lacteal of amyloid-β (Aβ) and apolipoprotein (apo) B were
determined with 3-D quantitative immunomicroscopy in the small intestine of mice maintained on low-fat (LF) control chow or diets enriched in
saturated fats (SFA) with/without probucol for 3 months (3 M) and 12 months (12 M). (A) The mean voxel intensity of small intestinal villi Aβ or
apoB are expressed per DAPI voxel intensity. One-way ANOVA followed by Tukey’s post hoc test was performed and the significance is indicated
with * (p < 0.05, n = 8). (B) The plasma concentration of Aβ was measured with ELISA. One-way ANOVA followed by Tukey’s post hoc test was
performed to compare the difference of total plasma Aβ, and the significance is indicated with alphabetical letters (p < 0.05, n = 8). (C) Correlation
coefficient between intestinal Aβ or apoB with cerebral IgG/apoB extravasation are also shown. Correlation coefficient was determined with
Pearson’s analysis (n = 24). (D) Correlation coefficient between intestinal Aβ or apoB with neuroinflammatory GFAP/COX-2 are also shown.
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modest but not significant effect on apoB retention at 12
months of intervention.GFAP and COX-2 are widely used measures of neuro-
vascular inflammation. Both measures were increased
principally within the cortex in mice maintained on a LF
Figure 5 Immunofluorescent micrographs of small intestinal Amyloid-β and apolipoprotein B. Representative immunofluorescent
micrographs of small intestinal amyloid-β (Aβ) and apolipoprotein (apo) B are shown in mice maintained on low-fat (LF) control chow or diets
enriched in saturated fats (SFA) with/without probucol for 3 months (3 M) and 12 months (12 M). Aβ and apoB are shown in yellow and red
respectively, and the nuclei are shown in blue. “Lu” and “La” indicate intestinal lumen and villi lacteal respectively, and the cell lining between Lu
and La are the absorptive enterocytes. The scale bar indicates 10 μm.
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of intervention. However, GFAP and COX-2 were mark-
edly elevated as a consequence of SFA in both CTX and
HPF. The co-provision of probucol had a remarkable
suppressive effect on these measures of neurovascular
inflammation essentially completely abolishing the SFA-
induced effect that persisted for the duration of inter-
vention. Collectively, probucol appears to protect BBB
integrity through the suppression of neurovascular in-
flammation in aged mice maintained on an SFA diet.
Another possible mechanism by which probucol pre-
vents the long-term high SFA induced BBB dysfunction
may attribute to the reduced BBB exposure to circulat-
ing Aβ that are associated with apoB lipoproteins. Indir-
ect evidence comes from studies in amyloid transgenic
mice, where it was reported that onset and progression
of amyloidosis was positively associated with the secretion
into blood of Aβ that was associated with nascent chylo-
micron [14]. The SFA diet used in this study was previously
demonstrated to increase the enterocytic association of Aβ
with nascent chylomicrons [11,12]. In other studies; probu-
col was shown to strongly suppress the chylomicron-Aβ in
mice fed an SFA enriched diet for 3 months [7]. Hence the
proposition that postprandial-Aβ is associated with age-
induced capillary dysfunction is worthy of consideration.
Enterocytic apoB (an obligatory structural element of
chylomicrons) is a useful surrogate marker of chylomicron
biosynthetic rates [15]. The abundance of Aβ that is colo-
calized with nascent chylomicrons is therefore a direct
measure of protein abundance per lipoprotein particle
assembled.
This study reports that mice maintained on a LF diet for
12 months had substantially elevated Aβ relative to nas-
cent chylomicrons within the absorptive epithelial cells of
the small intestine compared to 3 months LF control
mice. However, enterocytic apoB production remained
comparable. Long-term ingestion of SFA enriched dietsdoubled the enterocytic postprandial Aβ production con-
comitant with increased enterocytic apoB lipoprotein, sug-
gesting increased release of lipoproteins and Aβ into the
circulation. However, the enterocytic production of Aβ
was completely abolished by the co-provision of probucol
with the SFA diet. In mice, it is not feasible and perhaps
not relevant to measure postprandial chylomicron-Aβ in
plasma because of the limited sampling volume; separation
of plasma lipoprotein classes; the effects of anesthesia and
mimicking the ‘chronic’ (12 month) dietary intervention in
the context of a singular acute fat challenge. Nonetheless,
our data showed a significant increase in the plasma
Aβ by the long-term ingestion of SFA enriched diet.
The study also provided evidence of a quite strong positive
association between chylomicron-Aβ, cerebral-capillary
permeability and parenchymal apoB lipoprotein abun-
dance. Consistent with the notion that chylomicron-Aβ
per se, rather than chylomicron concentration is more
relevant to capillary integrity, there was a relatively poor
positive association of permeability with enterocytic apoB.
Furthermore, probucol had a substantial effect on entero-
cytic Aβ, but a weaker and non-significant effect on apoB
abundance. These data collectively suggest that probucol
may protect the BBB integrity through reduced BBB ex-
posure to postprandial lipoprotein-Aβ by attenuating the
enterocytic production of postprandial Aβ.
This is the first long-term intervention study showing
potential beneficial effects of probucol on cerebral capillary
integrity in the context of reducing risk for Alzheimer’s
disease. This study demonstrates persistent suppression by
probucol of neurovascular inflammation and differential
effects of capillary permeability in aged mice that had been
maintained on an SFA-enriched diet. The beneficial effects
of probucol on SFA-induced capillary dysfunction may
in part be a consequence of suppression of postprandial
lipoprotein-Aβ secretion and decreased vascular exposure,
and of its anti-oxidative/-inflammatory properties.




DL methionine 1.8 1.8
Sucrose 100 100
Wheat starch 472 308
Dextrinised starch 155 155
Cellulose 50 50
Canola oil 40 0
Cocoa butter 0 204
Calcium carbonate 13.1 13.1
Sodium chloride 2.6 2.6
Potassium citrate 1.0 1.0
Potassium dihydrogen phosphate 8.8 8.8
Potassium sulphate 1.6 1.6
AIN93G trace minerals 1.4 1.4
Choline chloride (65%) 2.5 2.5
AIN93G vitamins 10 10
Fat composition (w/w)
Total fat 4%
Saturated fatty acids C12:0 and less na 0.10%
Myristic acid 14:0 trace 0.05%
Pentadecanoic acid 15:0 na 0.01%
Palmitic acid 16:0 0.2% 5.16%
Magaric acid 17:0 na 0.05%
Stearic acid 18:0 0.1% 7.31%
Arachidic acid 20:0 na 0.24%
Behenic acid 22:0 na 0.04%
Tetracosanoic acid 24:0 na 0.03%
Palmitoleic acid 16:1 trace 0.05%
Heptadecenoic acid 17:1 na 0.01%
Oleic acid 18:1 n9 2.4% 6.62%
Gadoleic acid 20:1 trace 0.01%
Linoleic acid 18:2 n6 0.8% 0.67%
a Linolenic acid 18:3 n3 0.4% 0.05%
g Linolenic acid 18:3 n6 na not detected
Arachadonic acid 20:4 n6 trace not detected
EPA 20:5 n3 trace not detected
DPA 22:5 n3 na not detected
DHA 22:6 n3 trace not detected
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Animals and dietary/drug interventions
Wild-type female C57BL/6 J mice (6 weeks old) were pur-
chased from Animal Resources Centre (WA, Australia).
Groups of 16 mice were randomized to treatment groups
of LF control, high SFA, or high SFA supplemented with
probucol. The LF diet was standard rodent chow
(AIN93M) containing 4% polyunsaturated fats without
cholesterol or SFA. The SFA diet was semi-synthetic
chow contained 40% total energy as saturated fats de-
rived from cocoa butter (5% w/w palmitic 16:0, 7% ste-
aric 18:0) as described previously [4] and shown in
Table 2. Probucol was supplemented to the SFA diet at
a concentration of 1% (w/w), determined according to
previous studies [4,7,16,17]. Diets were prepared and
supplied by Specialty Feeds (WA, Australia). Probucol
was kindly provided by Sanofi-Aventis (France). The
mice were housed in individually ventilated cages with
controlled temperature (22˚C), air pressure, and 12 h
dark/light cycle, and had ad libitum access to the food
and water.
All procedures used in this study were approved by
National Health and Medical Research Council accre-
dited Animal Ethics Committee (Curtin University ap-
proval no. R34/08).
Sample collection and preparation
Samples were collected and prepared as described previ-
ously [5,11]. Briefly, at 3 and 12 months following diet-
ary/drug intervention, 8 mice from each intervention
group were euthanized under complete anesthesia with
pentobarbitone (45 mg/kg). Plasma sample was collected
from cardiac puncture. The brain tissues were collected
as described previously [5,6,8]. Briefly the brain was
carefully removed and washed in ice-chilled PBS as pre-
viously described. The tissues were fixed in 4% parafor-
maldehyde immediately to minimize the post-mortem
artifact for 24 h, then cryoprotected in 20% sucrose for
72 h at 4˚C. The tissues were then frozen in dry ice/iso-
pentane and stored at −80˚C. In all mice, the first centi-
meter of small intestine was also isolated and washed in
ice-chilled PBS and fixed in 4% paraformaldehyde for 24
h. The small intestinal tissues were then processed in a
tissue processor (TP1020, Leica Australia) and embed-
ded in paraffin wax.
Assessment of blood–brain barrier integrity
The integrity of BBB was assessed by the cerebral ex-
travasation of plasma-derived proteins, IgG (Mw 155
kDa) and apoB lipoproteins (molecular weight >2 × 107
kDa) as described previously [4-6,8,18,19]. Briefly, 20 μm
cryosections were prepared from the right hemisphere in
the approximate stereotaxic areas of 1.7 mm interaual
and 2.1 mm Bregma of each mouse brain. After a blockingwith 10% goat serum in PBS for 30 min, the sections were
incubated with goat anti-mouse IgG conjugated with
Alexa488 (1:50, Invitrogen, US) for 20 h at 4˚C for IgG
analysis. For apoB analysis, the sections were incubated
with rabbit anti-mouse apoB (1:200, Abcam, UK) for 20 h
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(1:200, Invitrogen) was then applied to the sections for 2 h
at 22˚C. DAPI staining was used to identify the cerebro-
vascular endothelial cells. Negative controls were included
for all immunofluorescent experiments and included re-
placement of the primary antibody with buffer, or an ir-
relevant serum. Fluorescent staining was not observed for
any negative control tissue preparations.
At a magnification of 200× (20× Zeiss Plan-Neofluar
objective with 10× mRM camera, 430 × 322 μm), a
minimum of five images per section were captured from
randomly selected areas of the cortex and hippocampal
formation respectively in the approximate stereotaxic
areas of 1.7 mm interaual and −2.1 mm Bregma. Each 3-
D image consisted of 12 Z-stack images and the distance
between Z-stack slices was 1.225 μm optimized by
Nyquist theory (2× oversampling in axial direction). The
optical densitometric sum for the protein of interest was
determined in three dimensions (1388 × 1040 pixels 2D
planes) utilizing the measurement tool of image analysis
software Volocity ver5 (PerkinElmer, UK). Fluorescence
within capillary vessels is excluded based on pre-set
threshold parameters and thereafter confirmed for each
image to ensure proper selection for parenchymal re-
gions of interest. Total optical densitometric for each 3-
D image was expressed as voxel intensity per volume
unit, and the mean of all images from each region was
used for the statistical comparison.
Measurement of neuroinflammation
The neuronal inflammatory responses following the dis-
ruption of BBB were measured with the immunodetec-
tion of GFAP and COX-2 as described previously [4,6].
The 20 μm cryosections were blocked with 5% goat
serum for 30 min. Either of rabbit anti-mouse GFAP
(1:200, Abcam) or rabbit anti-mouse COX-2 (1:200,
Abcam) antibody was added onto the sections, and incu-
bated for 20 h at 4˚C. Goat anti-rabbit IgG conjugated
with Alexa488 (1:200) was then applied to the sections
for 2 h at 22˚C. Semi-quantitative parenchymal abun-
dance of GFAP and COX-2 were determined within the
HPF and CTX as described for IgG and apo B.
Detection of small intestinal production/secretion of Aβ
and apoB
The immunofluorescent technique was utilized to detect
the production and secretion of Aβ and apoB from the
small intestine as described previously [7,20,21]. Briefly,
5 μm thick paraffin embedded small intestinal sections
were dewaxed for 1 h in xylene. After rehydration of sec-
tions, the heat mediated antigen retrieval was performed
in boiling water for 2 min. Following blocking with 20%
goat serum in PBS, the sections were incubated with
either rabbit anti-mouse Aβ (1:1000, Chemicon, US) orrabbit anti-mouse apoB (1:300, Abcam) for 20 h at 4˚C.
For Aβ detection, the sections were incubated with goat
anti-rabbit Ig conjugated with biotin (1:2000, DAKO) for
1 h, followed by incubation with avidin-Alexa546 (1:300,
Invitrogen) for 1 h. For apoB detection, the sections
were incubated with anti-rabbit IgG Alexa488 (1:200,
Invitrogen) for 1 h. The nuclei were stained with DAPI.
The staining in the enterocytes (production) and within
the lacteal (secretion) was observed with Axiovert 200
M. Semi-quantitative abundance of enterocytic Aβ and
apo B were determined as described for parenchymal
abundance of IgG and apoB.
Plasma lipids
The concentration of plasma total cholesterol and tri-
glycerides were measured with colorimetric assays as de-
scribed previously by using commercially available kits
(Randox, UK). Briefly, 2 μl of plasma samples or stan-
dards were loaded to 96-well microplates. 200 μl of reac-
tion solution was then added and incubated for 5 min at
37˚C. The optical absorbance was read at 550 nm.
Plasma NEFA were measured by a colourimetric assay
purchased from Wako according to the instructions pro-
vided by the manufacturer. Briefly, 7 μl of plasma sam-
ples or standards were loaded to 96-well microplate.
300 μl of Reagent 1 was added and incubated for 3 min
at 37˚C, then 150 μl of Reagent 2 was added for 4.5 min
at 37˚C. The optical absorbance was read at 550 nm.
Plasma amyloid-β
Plasma concentrations of mouse Aβ1–40 and 1–42 were
measured utilizing ELISA kits (Invitrogen, US) according
to the manufacturer’s instruction. One hundred micro-
liter of 4-fold diluted plasma or Aβ standards (Aβ1–40: 0,
1, 2.5, 5.0, 10.0, 25.0, 50.0, 100 pmol/L; Aβ1–42: 0, 0.1, 0.5,
1.0, 2.0, 5.0, 10.0, 20.0 pmol/L) were dispensed into wells
and incubated for overnight at 4˚C, then thoroughly
washed. The Aβ antibody conjugated with HRP was then
added and incubated for 1 h at room temperature. TMB
solution was added for 30 min in darkness, then the reac-
tion was terminated by adding the stopping solution. The
optical absorbance was measured at 450 nm.
Statistics
The number of the animals and immunomicrograph
samples collected for the quantitative analyses were
determined to produce sufficient statistical power to in-
vestigate the effects of Dietary/Drug interventions and
Duration/Aging that were also based on the published
previous studies [5,6,8]. In this study the data was nor-
mally distributed, hence one-way ANOVA followed by
Tukey’s or Bonferroni’s post hoc tests were conducted
to determine the statistical significance at p < 0.05 or
p < 0.01 (2-tailed).
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